Accordingly, although our RNA-seq assay and the subsequent PANTHER signaling pathway analysis points to the potential involvement of VEGF and EFGR signaling, their clinical significance in SFT remains unclear, as both RAS and TP53 genes are reportedly mutated in HCT116 and both genes are known to have interactions with VEGF or EFGR signaling [55,56]. This evidence concerns the gene TP53 and solitary fibrous tumor.